Briacell Therap (NASDAQ:BCTX) Issues Quarterly Earnings Results

Briacell Therap (NASDAQ:BCTX) issued its quarterly earnings results on Wednesday. The company reported ($1.50) earnings per share (EPS) for the quarter, FiscalAI reports.

Briacell Therap Trading Down 5.4%

Shares of NASDAQ:BCTX opened at $3.31 on Friday. The firm has a 50 day simple moving average of $3.79 and a 200-day simple moving average of $3.87. Briacell Therap has a twelve month low of $2.60 and a twelve month high of $13.43. The company has a market capitalization of $28.80 million, a PE ratio of -0.36 and a beta of 1.21.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Briacell Therap in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, the stock currently has an average rating of “Sell”.

Briacell Therap Company Profile

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. Its research is centered on treatments designed to stimulate a patient’s immune system to recognize and attack tumor cells, with an emphasis on advanced breast cancer and other solid tumors.

The company’s lead technology includes Bria-IMT, an off-the-shelf, whole-cell immunotherapy derived from a breast cancer cell line. BriaCell has also been developing Bria-OTS, a personalized immunotherapy approach intended to match treatment with a patient’s human leukocyte antigen profile.